Last Update 24 Apr 26
Fair value Decreased 21%AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals
The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.
Analyst Commentary
Recent research commentary on Amphastar Pharmaceuticals has centered on the tension between lower revenue guidance and the potential contribution of new products, particularly AMP-015 and AMP-007. While some analysts have reduced price targets and ratings, others see room for execution upside if management can deliver on product launches and margin goals.
The updated US$30 price target cited by one firm reflects a recalibration of expectations around revenue and profitability. It also assumes a higher future P/E multiple, which signals that some on the Street still see the business as capable of justifying a richer valuation if growth drivers materialize.
Across reports, revenue guidance and the approvals of AMP-015 and AMP-007 are common reference points. AMP-007 in particular is flagged as a key swing factor for achieving mid to high single digit revenue growth targets over time. For investors, the debate is less about the current guidance cut and more about how quickly these therapies can contribute meaningfully to the top line and support margins.
Bullish Takeaways
- Bullish analysts highlight that the assumed higher future P/E multiple in recent target updates reflects confidence that Amphastar can still support a premium valuation if it executes on new product launches and cost discipline.
- The successful approvals of AMP-015 and AMP-007 are viewed as important building blocks for future revenue, giving the company more shots on goal to support the mid to high single digit revenue growth framework cited in research.
- AMP-007 is repeatedly called out as a key contributor, with bullish analysts focusing on its potential to narrow the gap between revised revenue guidance and prior expectations if uptake and pricing land at the higher end of their internal scenarios.
- Even as price targets are reset to US$30, some bullish commentary points to the view that current share weakness tied to the lower revenue guidance may already reflect a good portion of the bad news. This could leave room for upside if the company outperforms these tempered expectations.
What's in the News
- From October 1, 2025 to December 31, 2025, Amphastar Pharmaceuticals repurchased 806,964 shares for US$20.5 million, representing 1.74% of its shares. (Key Developments)
- This activity brought total repurchases under the buyback announced on November 8, 2016 to 14,913,423 shares, or 31.42%, for an aggregate US$389.63 million. (Key Developments)
Valuation Changes
- Fair Value: Reduced from $38.00 to $30.00, representing a notable cut to the implied equity value per share.
- Discount Rate: Increased slightly from 6.78% to 6.98%, indicating a modestly higher required return being applied to future cash flows.
- Revenue Growth: The assumed long-term revenue growth rate decreased from 10.79% to 6.33%, indicating a more conservative topline outlook.
- Net Profit Margin: The assumed net profit margin moved from 21.23% to 12.68%, reflecting lower expected profitability on each dollar of revenue.
- Future P/E: The target future P/E multiple increased from 9.31x to 13.38x, suggesting a higher valuation multiple being used despite more cautious growth and margin inputs.
Key Takeaways
- Global commercialization of BAQSIMI and pipeline exclusivity could drive significant revenue and margin gains beyond current analyst expectations.
- Expanded domestic manufacturing and focus on innovative drugs position Amphastar for sustained growth, competitive advantage, and higher margins amid rising industry demand.
- Intensifying competition, revenue concentration risk, and high R&D costs threaten Amphastar's profitability as pricing pressures and generic entrants erode market share and margins.
Catalysts
About Amphastar Pharmaceuticals- A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.
- While analyst consensus sees the MannKind partnership accelerating BAQSIMI's sales growth, current expectations significantly understate its potential; with Amphastar now managing global commercialization, BAQSIMI's robust volume growth and pricing power could drive materially outsized revenue and EBITDA expansion, particularly as it cannibalizes legacy glucagon products and gains share internationally.
- Analysts broadly agree that the imminent pipeline launches (AMP-002, AMP-007, AMP-015, and AMP-018) can bolster revenue and earnings, but if Amphastar captures first-to-market or sole-supplier status for AMP-007 as suggested by management, and secures early approval for AMP-002, the resulting exclusivity periods and unmet demand may lead to a step change in both top-line growth and gross margin improvement beyond consensus forecasts.
- Amphastar's aggressive quadrupling of domestic manufacturing capacity uniquely positions it to capitalize on the accelerating industry shift toward U.S.-based drug production, helping it to secure high-value contracts, mitigate global supply chain risks, and structurally enhance net margins as other companies struggle with international disruptions and tariffs.
- Demographic tailwinds-specifically, the aging global population and rising chronic disease incidence-are likely to multiply demand for Amphastar's specialty injectables and inhalation therapies over the next decade, supporting sustained double-digit revenue growth as the company broadens its branded and proprietary product offerings.
- Amphastar's intensifying focus on R&D and expansion into high-value innovative drugs, combined with its proven track record of strategic M&A, positions the company to outpace generic drug competitors, diversify revenue streams, and achieve substantial long-term earnings growth from both new internally developed and acquired proprietary products.
Amphastar Pharmaceuticals Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more optimistic perspective on Amphastar Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
- The bullish analysts are assuming Amphastar Pharmaceuticals's revenue will grow by 6.3% annually over the next 3 years.
- The bullish analysts assume that profit margins will shrink from 13.6% today to 12.7% in 3 years time.
- The bullish analysts expect earnings to reach $109.8 million (and earnings per share of $2.24) by about April 2029, up from $98.1 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 13.5x on those 2029 earnings, up from 9.5x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 16.1x.
- The bullish analysts expect the number of shares outstanding to decline by 3.75% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Intensifying competition, particularly in legacy products such as glucagon and epinephrine, has led to both price erosion and unit volume declines, which are likely to continue shrinking revenues and compressing gross margins over the long term.
- Overreliance on top-performing products like BAQSIMI and Primatene MIST increases revenue concentration risk; should demand slow, competitors enter, or pricing pressure increase, future revenues and earnings would be disproportionately affected.
- High and rising research and development expenses, up 14 percent year-over-year and driven by new proprietary projects and complex generics, may not be matched by equivalent new product revenue if regulatory delays, crowded markets, or pipeline failures occur, thus negatively impacting net margins and earnings stability.
- Flat top-line sales guidance and explicit management expectations of margin contraction due to competitive price pressures on existing products signal that earnings growth could stagnate or decline as industry-wide pricing power erodes and healthcare cost containment intensifies.
- Growing generic and biosimilar competition, particularly in crowded markets like GLP-1, as well as purchasing pressure from consolidating pharmacy benefit managers, could further erode Amphastar's market share and limit its ability to achieve future revenue and margin expansion.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bullish price target for Amphastar Pharmaceuticals is $30.0, which represents up to two standard deviations above the consensus price target of $26.86. This valuation is based on what can be assumed as the expectations of Amphastar Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $30.0, and the most bearish reporting a price target of just $22.0.
- In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $865.5 million, earnings will come to $109.8 million, and it would be trading on a PE ratio of 13.5x, assuming you use a discount rate of 7.0%.
- Given the current share price of $21.01, the analyst price target of $30.0 is 30.0% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Amphastar Pharmaceuticals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
